While Pfizer’s earlier Prevnar 13 and Prevnar 10 have made a dent in the global burden of invasive pneumococcal disease, the bacterial infection remains a threat. According to 2021 estimates ...

It covers 15 different pneumococcal serotypes – two more than Pfizer's current Prevnar 13 shot – and has been approved for use in patients aged 18 or over. Pfizer's updated 20-valent vaccine ...

The bulk of Prevnar 13 sales come from use in adults ... The shot also includes two "conserved" pneumococcal proteins – antigens that seem always to be present in the bacterium regardless ...

Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from ...

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by ...

SK bioscience and Sanofi have announced plans for global Phase III studies, which will assess the safety and immunogenicity ...

Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...

Medicare Advantage plans, sometimes called Part C, also cover the pneumonia vaccine. Pneumococcal vaccines can prevent common bacterial infections from Streptococcus pneumoniae. There are two ...

Simply defined as an extension of the benefit of protection from immunization in those immunized to those unimmunized in a community, herd effect was key to the success of Prevnar in North America.

Vaxcyte, Inc. (NASDAQ:PCVX) is a biotechnology company that is developing next-generation pneumococcal conjugate ... 20 serotypes similar to Pfizer’s Prevnar 20 and demonstrated superiority ...